相关临床试验
6
5 进行中
药物批准
74
批准总数
监管机构
2
监管机构数
成立时间
2004
进行中（未招募）
4
66.7%
已完成
1
16.7%
尚未招募
1
16.7%
- Sangamo Therapeutics' gene therapy ST-920 (isaralgagene civaparvovec) is advancing toward accelerated FDA approval with a BLA submission planned for the latter half of 2025, following positive Phase 1/2 STAAR trial data. - The global Fabry disease treatment market was valued at USD 2.62 billion in 2025 and is projected to reach USD 5.92 billion by 2035, growing at a CAGR of 8.47%. - Enzyme replacement therapy remains the standard of care with 76.10% market share in 2025, while gene therapies and oral chaperone treatments are expected to reshape the treatment landscape. - In 2024, approximately 9,200 diagnosed prevalent cases of Fabry disease were estimated in the United States, representing 52% of the total across the seven major markets.
- ElevateBio achieved its sixth consecutive year of revenue growth while maintaining a 98% manufacturing batch success rate across cell therapy, viral vector, and mRNA production at its BaseCamp facility. - The company appointed Christopher Murphy as CEO to lead expansion efforts, leveraging his 35+ years of experience in biopharmaceutical development and manufacturing operations. - ElevateBio expanded its gene editing capabilities by adding targeted insertion and epigenetic editing modalities to Life Edit's platform, while supporting 18 preclinical and clinical-stage programs. - The company completed construction of a new Pittsburgh facility expected to be operational in 2027 and expanded its Waltham manufacturing capacity by 30%.
- Q32 Bio appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to oversee the ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata treatment. - Dr. Sipos brings over 25 years of immunology and inflammation drug development experience from leadership roles at Biogen, Sanofi Genzyme, and Eli Lilly. - The company expects topline results from Part B of the SIGNAL-AA Phase 2a trial in the first half of 2026 for their novel anti-IL-7Rα antibody therapy. - Bempikibart represents a novel therapeutic approach targeting IL-7 and TSLP signaling pathways to treat alopecia areata, which affects approximately 700,000 Americans.
- Sanofi and Novo Nordisk have reached settlements with Maine and Minnesota attorneys general to cap insulin prices at $35 per month through 2029. - The agreements cover major insulin products including Lantus, Admelog, Novolog, and Tresiba, available to all consumers regardless of insurance status. - Minnesota's settlement with Novo Nordisk will reduce insulin costs by over 90% for many patients, following similar agreements with Eli Lilly and Sanofi. - The settlements resolve lawsuits alleging deceptive pricing practices where companies charged high list prices while negotiating lower rates through pharmacy benefit manager rebates.
- Propionic acid, a short-chain fatty acid produced by gut bacteria, may play a beneficial role in multiple sclerosis (MS) pathology by influencing immune and nervous systems. - Supplementation with propionate demonstrates immunoregulatory, neuroprotective, and neurogenerative effects in MS patients, potentially counteracting the pro-inflammatory state. - Propionic acid could improve outcomes when used with immune-modulating therapy by regulating the immune system and decreasing gut and blood-brain barrier permeability. - Further clinical trials are needed to evaluate the efficacy and safety of propionic acid supplementation in MS patients as a complementary therapeutic strategy.
• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.
- The European Commission has authorized Cablivi (caplacizumab) as the first specific treatment for acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. - Clinical trials involving 220 adults demonstrated Cablivi significantly reduced platelet count normalization time and decreased aTTP-related complications when added to standard care, with no deaths reported in the treatment group. - The approval marks a significant advancement in aTTP treatment, where current standard therapy still carries up to 20% mortality rate, with Cablivi also under priority review by the FDA.
